ATC Group: R01AD12 Fluticasone furoate

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R01AD12 in the ATC hierarchy

Level Code Title
1 R Respiratory system
2 R01 Nasal preparations
3 R01A Decongestants and other nasal preparations for topical use
4 R01AD Corticosteroids
5 R01AD12 Fluticasone furoate

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
NASAL - Nasal 0.11 mg

Active ingredients in R01AD12

Active Ingredient Description
Fluticasone furoate

Fluticasone furoate is a synthetic trifluorinated corticosteroid that possesses a very high affinity for the glucocorticoid receptor and has a potent anti-inflammatory action.

Related product monographs

Title Information Source Document Type  
AVAMYS Nasal spray, suspension European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Lithuania (LT)

Mexico (MX)

Netherlands (NL)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.